Prime Medicine Appoints Svetlana Makhni as CFO Ahead of Wilson Disease and AATD Clinical Trials
Prime Medicine named Svetlana Makhni CFO to oversee financial planning, investor relations and corporate development. Makhni brings over 20 years of biotech finance and investment-banking experience, including strategic partnerships with Ipsen and Gilead, as the company readies Wilson Disease and Alpha-1 Antitrypsin Deficiency programs for clinical entry.
1. CFO Appointment Details
Prime Medicine has appointed Svetlana Makhni as Chief Financial Officer, entrusting her with oversight of financial operations, investor relations, financial planning and corporate development functions. The move aligns with the company's strategy to strengthen its leadership team ahead of key clinical milestones.
2. Executive Experience and Track Record
Makhni brings over two decades of experience in biotech finance and investment banking. Her previous roles include CFO of Marengo Therapeutics, where she led strategic partnerships with Ipsen and Gilead, and senior finance positions at Escient Pharmaceuticals and BMO Capital Markets.
3. Strategic Implications for Clinical Programs
The appointment positions Prime Medicine to optimize its capital strategy as it prepares to enter the clinic for Wilson Disease and Alpha-1 Antitrypsin Deficiency. Makhni's expertise is expected to support fundraising, strategic alliances and financial planning for these high-value programs.